Bibliografia
1. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. 2009, 50, 227-42.
2. Viread, scheda tecnica (http://www.paginesanitarie.com/skfarmaci)
3. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Washington MK, Sorbel J, Anderson J, Snow-Lampart A, Mondou E, Quinn J, Rousseau F. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008, 359, 2442-55.
4. Marcellin P, Buti M, Krastev Z, Germanidis G, Kaita K, Kotzev I, Buggisch P, Weilert F, Trinh H, Gurel S, Heathcote J, Sorbel J, Anderson J, Mondou E, Rousseau F. Three Years of Tenofovir Disoproxil Fumarate (TDF) Treatment in HBeAg-Negative Patients (HBeAg–) with Chronic Hepatitis B (Study 102). 60th Annual Meeting of AASLD 2009 (Poster # 481)
5. Heathcote J, Gane E, deMan R, Lee Flisiak S, Manns M, Tchernev K, Kurdas O, Shiffman M, Marcellin P, Sorbel J, Anderson J, Mondou E, Rousseau F. Three Years of Tenofovir Disoproxil Fumarate (TDF) Treatment in HBeAg-Positive Patients (HBeAg+) With Chronic Hepatitis B (Study 103). 60th Annual Meeting of AASLD 2009 (Poster # 483)
6. Buti M, Hadziyannis S, Mathurin P, Urbanek P, Sherman M, Strasser S, Wang C , Petersen J, Heathcote J, Marcellin P, Sorbel J, Mondou E, Anderson J, Rousseau F. Two Years Safety and Efficacy of Tenofovir Disoproxil Fumarate (TDF) in Patients With HBV-Induced Cirrhosis. 44th Annual Meeting of EASL 2009 (Oral #21)
7. Snow-Lampart A, Chappell B, Sorbel J, Borroto-Esoda K, Miller M. Evaluation of Potential Virologic Resistance in HBV Polymerase Among Subjects with Persistent Viremia Following up to 144 Weeks of Therapy with Tenofovir DF. 45th Annual Meeting of EASL 2010 (Poster #1022)
8. van Bömmel F, Zöllner B, Sarrazin C, Spengler U, Hüppe D, Möller B, Feucht HH, Wiedenmann B, Berg T. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology. 2006 Aug;44(2):318-25.
9. van Bömmel F, de Man RA, Wedemeyer H et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology. 2010, 51, 73-80.
10. Berg T, Marcellin P, Zoulim F, Moller B, Trinh H, Chan S, Suarez E, Lavocat F, Snow-Lampart A, Frederick D, Sorbel J, Borroto-Esoda K, Oldach D, Rousseau F. Tenofovir Is Effective Alone or with Emtricitabine in Adefovir-Treated Patients with Chronic-Hepatitis B Virus Infection. Gastroenterology. 2010 Jun 20. [Epub ahead of print]
11. Patterson SJ, George J, Strasser SI, Lee AU, Sievert W, Nicoll AJ, Desmond PV, Roberts SK, Locarnini S, Bowden S, Angus PW. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut (2010) (in press).
12. Levrero M, Cimino L, Lampertico P, Viganò M, Gaeta GB, Brancaccio P, Sagnelli E, Messina V, Raimondo G, Marzano A, Fagiuoli S, G, Niro G, Santantonio T, Di Marco V, Mazzella G, Di Costanzo , Angelico M, Pierconti S, Savà C on behalf of the OptiB Study Group. OptiB ‐ a multicenter prospective open label study on Tenofovir (TDF) for chronic hepatitis B patients with suboptimal response to adefovir (ADV) or ADV/LAM treatment. Hepatology 2010, 10, S138 (AASLD 2010 Annual Meeting)
13. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology. 2009, 137, 1593-608.
14. Tan J, Degertekin B, Wong SN, Husain M, Oberhelman K, Lok AS. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J Hepatol. 2008, 48, 391-8.